Company Profile For Valeant Pharmaceuticals International

Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

BRIEF: For the nine months ended 30 September 2009, Valeant Pharmaceuticals International's revenues increased 24% to $589.9M. Net income from continuing operations totaled $101.4M vs. a loss of $56.7M. Revenues reflect increased specialty Pharmaceuticals segment income and a rise in Branded Generic-Latin America segment sales. Net income also reflects decreased selling, general & administrative expenses and lower interest expenses.

Valeant Pharmaceuticals International
One Enterprise
Aliso Viejo   CA   92656
P: +1949.4616000

2331